M. Dong

发表

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Xudong Wu, Bao-feng Wang, D. Guo, 2020, Frontiers in Immunology.

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

Yue He, T. Lei, Bao-feng Wang, 2020, Cancer Gene Therapy.

TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling

Dan Liu, Hongtao Zhu, Shijun Huang, 2022, Theranostics.

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Xudong Wu, Bao-feng Wang, D. Guo, 2022, Journal for ImmunoTherapy of Cancer.